TP53 突变型急性髓系白血病采用不断发展的一线治疗方案的结果：异基因干细胞移植对生存的影响。 - Suppr

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.

作者信息

Badar Talha, Atallah Ehab, Shallis Rory M, Goldberg Aaron D, Patel Anand, Abaza Yasmin, Bewersdorf Jan P, Saliba Antoine N, Correia Guilherme Sacchi De Camargo, Murthy Guru, Duvall Adam, Burkart Madelyn, Stahl Maximilian, Liu Yuanhang, Dinner Shira, Palmisiano Neil, Litzow Mark R, Foran James M

机构信息

Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA.

Division of Hematology and Medical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

出版信息

Am J Hematol. 2022 Jul;97(7):E232-E235. doi: 10.1002/ajh.26546. Epub 2022 Mar 30.

DOI:10.1002/ajh.26546

PMID:35338673

Abstract

摘要

相似文献

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.TP53 突变型急性髓系白血病采用不断发展的一线治疗方案的结果：异基因干细胞移植对生存的影响。

Am J Hematol. 2022 Jul;97(7):E232-E235. doi: 10.1002/ajh.26546. Epub 2022 Mar 30.

Transplant or no transplant for mutated AML.突变型急性髓系白血病是否进行移植

Oncotarget. 2024 Oct 1;15:674-676. doi: 10.18632/oncotarget.28652.

Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.TP53 突变的急性髓系白血病非西班牙裔黑人患者接受疾病导向治疗、异基因造血干细胞移植的差异。

Cancer. 2023 Mar 15;129(6):934-945. doi: 10.1002/cncr.34604. Epub 2022 Dec 21.

Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.伴有 17 号染色体异常的急性髓系白血病或骨髓增生异常综合征，以及造血干细胞移植与否的长期预后。

Leuk Res. 2020 Aug;95:106402. doi: 10.1016/j.leukres.2020.106402. Epub 2020 Jun 18.

Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with mutations.影响伴有突变的急性髓系白血病/骨髓增生异常综合征患者异基因移植后生存的预后因素。

Blood. 2018 Jun 28;131(26):2989-2992. doi: 10.1182/blood-2018-02-832360. Epub 2018 May 16.

Current status and new treatment approaches in TP53 mutated AML.TP53 基因突变型 AML 的现状和新的治疗方法。

Best Pract Res Clin Haematol. 2019 Jun;32(2):134-144. doi: 10.1016/j.beha.2019.05.004. Epub 2019 May 11.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.骨髓增生异常综合征和继发性急性髓系白血病中的基因异常：对干细胞移植结果的影响。

Blood. 2017 Apr 27;129(17):2347-2358. doi: 10.1182/blood-2016-12-754796. Epub 2017 Feb 21.

Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.TP53突变、单倍体核型和既往髓系疾病对异基因造血干细胞移植时未缓解的急性髓系白血病的预后影响。

Bone Marrow Transplant. 2021 Feb;56(2):334-346. doi: 10.1038/s41409-020-01016-9. Epub 2020 Aug 5.

Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.异基因造血干细胞移植可改善 ASXL1 突变的急性髓系白血病患者的生存。

Hematology. 2021 Dec;26(1):340-347. doi: 10.1080/16078454.2021.1905356.

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.接受异基因造血干细胞移植治疗的高危急性髓系白血病患者的TP53突变

Br J Haematol. 2016 Mar;172(6):914-22. doi: 10.1111/bjh.13912. Epub 2016 Jan 13.

引用本文的文献

Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management.急性髓系白血病：诊断、治疗与管理的最新进展

Cancers (Basel). 2025 Jul 18;17(14):2387. doi: 10.3390/cancers17142387.

Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML.异基因干细胞移植的发展：主要聚焦于急性髓系白血病

Cells. 2025 Apr 10;14(8):572. doi: 10.3390/cells14080572.

Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.TP53 突变的急性髓系白血病缓解期患者接受异基因干细胞移植的障碍

Bone Marrow Transplant. 2025 Apr 11. doi: 10.1038/s41409-025-02590-6.

Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.TP53 突变型急性髓系白血病和骨髓增生异常综合征的移植结局：一家移植中心 63 例患者的经验

Int J Hematol. 2025 Jun;121(6):820-832. doi: 10.1007/s12185-025-03951-z. Epub 2025 Feb 26.

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.急性髓系白血病：2025年诊断、风险分层及管理的最新进展

Am J Hematol. 2025 May;100(5):860-891. doi: 10.1002/ajh.27625. Epub 2025 Feb 12.

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation.TP53突变体等位基因频率和细胞遗传学决定了MDS/AML移植的预后分组。

Blood Adv. 2025 Jun 10;9(11):2845-2854. doi: 10.1182/bloodadvances.2024014499.

T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.使用质谱流式细胞术进行的T细胞免疫聚类分析可识别急性髓系白血病患者的独特亚组。

Blood Adv. 2025 Jan 28;9(2):239-243. doi: 10.1182/bloodadvances.2024014553.

What have we learned about TP53-mutated acute myeloid leukemia?关于TP53突变的急性髓系白血病，我们了解到了什么？

Blood Cancer J. 2024 Nov 19;14(1):202. doi: 10.1038/s41408-024-01186-5.

Transplant or no transplant for mutated AML.突变型急性髓系白血病是否进行移植

Oncotarget. 2024 Oct 1;15:674-676. doi: 10.18632/oncotarget.28652.

Patients with -Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.接受强化诱导治疗的携带 - 突变的急性髓系白血病患者因挽救治疗率较高而有更好的预后：一项单机构回顾性研究。

Cancers (Basel). 2024 Aug 7;16(16):2784. doi: 10.3390/cancers16162784.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献